WT1 Antibody [J23C5] Datasheet

Biological Description

Specificity	WT1 Antibody [J23C5] detects endogenous levels of total WT1 protein.
Background	Wilms’ tumor 1 (WT1) is a transcription factor encoded by the WT1 gene and is widely expressed during development, particularly in tissues of the genitourinary system, mesothelium, and hematopoietic compartments, where it exerts essential regulatory functions in organ formation and cell‑type specification. It belongs to a family of C2H2‑type zinc‑finger DNA‑binding proteins and contains multiple transcriptional regulatory domains, including an N‑terminal proline‑ and glutamine‑rich region with separable activation and repression motifs, as well as four C‑terminal zinc‑finger repeats that mediate sequence‑specific DNA binding and RNA‑interaction surfaces. Alternative splicing and post‑translational modifications generate multiple WT1 isoforms that differ in their N‑terminal sequence, inclusion of a 17‑amino‑acid insert, and presence or absence of the KTS triplet between the third and fourth zinc fingers, each of which can influence target‑gene selection and transcriptional output. WT1 can function as both a transcriptional activator and repressor, modulating expression of genes involved in proliferation, differentiation, and apoptosis, and it interfaces with coregulatory complexes that include histone‑modifying enzymes and RNA‑processing factors, thereby coupling transcriptional control to chromatin architecture and post‑transcriptional regulation. WT1 coordinates the balance between survival and proliferation of metanephric mesenchyme and promotes nephron differentiation, and in mesothelial and sex‑cord‑derived tissues, it regulates lineage identity and structural integrity. Mutations and dysregulation of WT1 are associated with congenital genitourinary defects such as Denys–Drash, Frasier, and WAGR syndromes, and loss‑of‑function or mislocalized WT1 correlates with Wilms’ tumor and impaired renal morphogenesis, whereas aberrantly expressed or overexpressed WT1 isoforms are detected in leukemias and solid tumors, where they can drive oncogenic gene programs.

Specificity

WT1 Antibody [J23C5] detects endogenous levels of total WT1 protein.

Background

Wilms’ tumor 1 (WT1) is a transcription factor encoded by the WT1 gene and is widely expressed during development, particularly in tissues of the genitourinary system, mesothelium, and hematopoietic compartments, where it exerts essential regulatory functions in organ formation and cell‑type specification. It belongs to a family of C2H2‑type zinc‑finger DNA‑binding proteins and contains multiple transcriptional regulatory domains, including an N‑terminal proline‑ and glutamine‑rich region with separable activation and repression motifs, as well as four C‑terminal zinc‑finger repeats that mediate sequence‑specific DNA binding and RNA‑interaction surfaces. Alternative splicing and post‑translational modifications generate multiple WT1 isoforms that differ in their N‑terminal sequence, inclusion of a 17‑amino‑acid insert, and presence or absence of the KTS triplet between the third and fourth zinc fingers, each of which can influence target‑gene selection and transcriptional output. WT1 can function as both a transcriptional activator and repressor, modulating expression of genes involved in proliferation, differentiation, and apoptosis, and it interfaces with coregulatory complexes that include histone‑modifying enzymes and RNA‑processing factors, thereby coupling transcriptional control to chromatin architecture and post‑transcriptional regulation. WT1 coordinates the balance between survival and proliferation of metanephric mesenchyme and promotes nephron differentiation, and in mesothelial and sex‑cord‑derived tissues, it regulates lineage identity and structural integrity. Mutations and dysregulation of WT1 are associated with congenital genitourinary defects such as Denys–Drash, Frasier, and WAGR syndromes, and loss‑of‑function or mislocalized WT1 correlates with Wilms’ tumor and impaired renal morphogenesis, whereas aberrantly expressed or overexpressed WT1 isoforms are detected in leukemias and solid tumors, where they can drive oncogenic gene programs.

Usage Information

Application

WB, IP, IHC, IF

Dilution

WB	IP	IHC	IF
1:1000	1:50	1:100	1:200

Reactivity

Human

Source

Rabbit Monoclonal Antibody

MW

51-60 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/15653840/
https://pubmed.ncbi.nlm.nih.gov/24927120/

Application Data

WB

Validated by Selleck

Lane 1: K562, Lane 2: OVCAR-3